Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells

Oncotarget

Volumn 5, Issue 13, 2014, Pages 4799-4810

  Schmidt, Sebastian ^a   Liu, Guoxing ^a   Liu, Guilai ^a   Yang, Wenting ^a   Honisch, Sabina ^a   Pantelakos, Stavros ^a,b   Stournaras, Christos ^a,b   Hönig, Arnd ^c   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

2 APB; Akt; Apoptosis; SH 6; SOCE

Indexed keywords

2 AMINOETHOXYDIPHENYLBORANE; CALCIUM; CALCIUM CHANNEL; CALCIUM RELEASE ACTIVATED CALCIUM CHANNEL 1; CISPLATIN; FURA 2; ION CHANNEL; PHOSPHATIDYLSERINE; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; STROMAL INTERACTION MOLECULE 1; 2-AMINOETHOXYDIPHENYL BORATE; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BORON DERIVATIVE; EMD 638683; HYDRAZINE DERIVATIVE; IMMEDIATE EARLY PROTEIN; MEMBRANE PROTEIN; ORAI1 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; SERUM-GLUCOCORTICOID REGULATED KINASE; SH-6 COMPOUND; STIM1 PROTEIN, HUMAN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CALCIUM DEPLETION; CALCIUM SIGNALING; CALCIUM TRANSPORT; CARCINOMA CELL; CELL SURVIVAL; FLOW CYTOMETRY; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; OVARY CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THERAPY RESISTANCE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; BORON COMPOUNDS; CALCIUM; CALCIUM CHANNELS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDRAZINES; IMMEDIATE-EARLY PROTEINS; MEMBRANE PROTEINS; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; PHOSPHATIDYLINOSITOLS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84905055572     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2035     Document Type: Article

References (100)

1. Becchetti A and Arcangeli A. Integrins and ion channels in cell migration: implications for neuronal development, wound healing and metastatic spread. Adv Exp Med Biol. 2010; 674:107-123.
2. Burgoyne RD. Neuronal calcium sensor proteins: generating diversity in neuronal Ca2+ signalling. Nat Rev Neurosci. 2007; 8(3):182-193.
3. Orrenius S, Zhivotovsky B and Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003; 4(7):552-565.
4. Roderick HL and Cook SJ. Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival. Nat Rev Cancer. 2008; 8(5):361-375.
5. Salter RD and Watkins SC. Dendritic cell altered states: what role for calcium? Immunol Rev. 2009; 231(1):278-288.
6. Prakriya M, Feske S, Gwack Y, Srikanth S, Rao A and Hogan PG. Orai1 is an essential pore subunit of the CRAC channel. Nature. 2006; 443(7108):230-233.
7. Putney JW, Jr. New molecular players in capacitative Ca2+ entry. J Cell Sci. 2007; 120(Pt 12):1959-1965.
8. Vig M, Peinelt C, Beck A, Koomoa DL, Rabah D, Koblan-Huberson M, Kraft S, Turner H, Fleig A, Penner R and Kinet JP. CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science. 2006; 312(5777):1220-1223.
9. Yeromin AV, Zhang SL, Jiang W, Yu Y, Safrina O and Cahalan MD. Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. Nature. 2006; 443(7108):226-229.
10. Zhang SL, Kozak JA, Jiang W, Yeromin AV, Chen J, Yu Y, Penna A, Shen W, Chi V and Cahalan MD. Store-dependent and-independent modes regulating Ca2+ release-activated Ca2+ channel activity of human Orai1 and Orai3. J Biol Chem. 2008; 283(25):17662-17671.
11. Fahrner M, Muik M, Derler I, Schindl R, Fritsch R, Frischauf I and Romanin C. Mechanistic view on domains mediating STIM1-Orai coupling. Immunol Rev. 2009; 231(1):99-112.
12. Peinelt C, Vig M, Koomoa DL, Beck A, Nadler MJ, Koblan-Huberson M, Lis A, Fleig A, Penner R and Kinet JP. Amplification of CRAC current by STIM1 and CRACM1 (Orai1). Nat Cell Biol. 2006; 8(7):771-773.
13. Penna A, Demuro A, Yeromin AV, Zhang SL, Safrina O, Parker I and Cahalan MD. The CRAC channel consists of a tetramer formed by Stim-induced dimerization of Orai dimers. Nature. 2008; 456(7218):116-120.
14. Smyth JT, Hwang SY, Tomita T, DeHaven WI, Mercer JC and Putney JW. Activation and regulation of store-operated calcium entry. J Cell Mol Med. 2010; 14(10):2337-2349.
15. Zhang SL, Yu Y, Roos J, Kozak JA, Deerinck TJ, Ellisman MH, Stauderman KA and Cahalan MD. STIM1 is a Ca2+ sensor that activates CRAC channels and migrates from the Ca2+ store to the plasma membrane. Nature. 2005; 437(7060):902-905.
16. Bergmeier W, Weidinger C, Zee I and Feske S. Emerging roles of store-operated Ca(2+) entry through STIM and ORAI proteins in immunity, hemostasis and cancer. Channels. 2013; 7(4).
17. Capiod T. The need for calcium channels in cell proliferation. Recent patents on anti-cancer drug discovery. 2013; 8(1):4-17.
18. Courjaret R and Machaca K. STIM and Orai in cellular proliferation and division. Frontiers in bioscience. 2012; 4:331-341.
19. Moccia F, Dragoni S, Lodola F, Bonetti E, Bottino C, Guerra G, Laforenza U, Rosti V and Tanzi F. Store-dependent Ca(2+) entry in endothelial progenitor cells as a perspective tool to enhance cell-based therapy and adverse tumour vascularization. Current medicinal chemistry. 2012; 34:5802-5818.
20. Prevarskaya N, Skryma R and Shuba Y. Calcium in tumour metastasis: new roles for known actors. Nat Rev Cancer. 2011; 11(8):609-618.
21. Ogawa A, Firth AL, Smith KA, Maliakal MV and Yuan JX. PDGF enhances store-operated Ca2+ entry by upregulating STIM1/Orai1 via activation of Akt/mTOR in human pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol. 2012; 302(2):C405-411.
22. Eylenstein A, Gehring EM, Heise N, Shumilina E, Schmidt S, Szteyn K, Munzer P, Nurbaeva MK, Eichenmuller M, Tyan L, Regel I, Foller M, Kuhl D, SoboloffJ, Penner R and Lang F. Stimulation of Ca2+-channel Orai1/STIM1 by serum-and glucocorticoid-inducible kinase 1 (SGK1). FASEB J. 2011; 25(6):2012-2021.
23. Borst O, Schmidt EM, Munzer P, Schonberger T, Towhid ST, Elvers M, Leibrock C, Schmid E, Eylenstein A, Kuhl D, May AE, Gawaz M and Lang F. The serum-and glucocorticoid-inducible kinase 1 (SGK1) influences platelet calcium signaling and function by regulation of Orai1 expression in megakaryocytes. Blood. 2012; 119(1):251-261.
24. Eylenstein A, Schmidt S, Gu S, Yang W, Schmid E, Schmidt EM, Alesutan I, Szteyn K, Regel I, Shumilina E and Lang F. Transcription factor NF-kappaB regulates expression of pore-forming Ca2+ channel unit, Orai1, and its activator, STIM1, to control Ca2+ entry and affect cellular functions. J Biol Chem. 2012; 287(4):2719-2730.
25. Lang F, Bohmer C, Palmada M, Seebohm G, Strutz-Seebohm N and Vallon V. (Patho)physiological significance of the serum-and glucocorticoid-inducible kinase isoforms. Physiol Rev. 2006; 86(4):1151-1178.
26. Baryshnikov SG, Pulina MV, Zulian A, Linde CI and Golovina VA. Orai1, a critical component of store-operated Ca2+ entry, is functionally associated with Na+/Ca2+ exchanger and plasma membrane Ca2+ pump in proliferating human arterial myocytes. Am J Physiol Cell Physiol. 2009; 297(5):C1103-C1112.
27. Berra-Romani R, Mazzocco-Spezzia A, Pulina MV and Golovina VA. Ca2+ handling is altered when arterial myocytes progress from a contractile to a proliferative phenotype in culture. Am J Physiol Cell Physiol. 2008; 295(3):C779-C790.
28. Faouzi M, Hague F, Potier M, Ahidouch A, Sevestre H and Ouadid-Ahidouch H. Down-regulation of Orai3 arrests cell-cycle progression and induces apoptosis in breast cancer cells but not in normal breast epithelial cells. J Cell Physiol. 2011; 226(2):542-551.
29. Motiani RK, Abdullaev IF and Trebak M. A novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells. J Biol Chem. 2010; 285(25):19173-19183.
30. Qu B, Al-Ansary D, Kummerow C, Hoth M and Schwarz EC. ORAI-mediated calcium influx in T cell proliferation, apoptosis and tolerance. Cell calcium. 2011; 50(3):261-269.
31. Schmid E, Bhandaru M, Nurbaeva MK, Yang W, Szteyn K, Russo A, Leibrock C, Tyan L, Pearce D, Shumilina E and Lang F. SGK3 regulates Ca(2+) entry and migration of dendritic cells. Cell Physiol Biochem. 2012; 30(6):1423-1435.
32. Chen YF, Chiu WT, Chen YT, Lin PY, Huang HJ, Chou CY, Chang HC, Tang MJ and Shen MR. Calcium store sensor stromal-interaction molecule 1-dependent signaling plays an important role in cervical cancer growth, migration, and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(37):15225-15230.
33. Flourakis M, Lehen'kyi V, Beck B, Raphael M, Vandenberghe M, Abeele FV, Roudbaraki M, Lepage G, Mauroy B, Romanin C, Shuba Y, Skryma R and Prevarskaya N. Orai1 contributes to the establishment of an apoptosis-resistant phenotype in prostate cancer cells. Cell death & disease. 2010; 1:e75.
34. Prevarskaya N, Ouadid-Ahidouch H, Skryma R and Shuba Y. Remodelling of Ca2+ transport in cancer: how it contributes to cancer hallmarks? Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2014; 369(1638):20130097.
35. Lang F, Friedrich F, Kahn E, Woll E, Hammerer M, Waldegger S, Maly K and Grunicke H. Bradykinin-induced oscillations of cell membrane potential in cells expressing the Ha-ras oncogene. The Journal of biological chemistry. 1991; 266(8):4938-4942.
36. Berridge MJ, Bootman MD and Lipp P. Calcium-a life and death signal. Nature. 1998; 395(6703):645-648.
37. Berridge MJ, Bootman MD and Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nature reviews Molecular cell biology. 2003; 4(7):517-529.
38. Berridge MJ, Lipp P and Bootman MD. The versatility and universality of calcium signalling. Nature reviews Molecular cell biology. 2000; 1(1):11-21.
39. Lang F, Busch GL, Ritter M, Volkl H, Waldegger S, Gulbins E and Haussinger D. Functional significance of cell volume regulatory mechanisms. Physiological reviews. 1998; 78(1):247-306.
40. Parekh AB and Penner R. Store depletion and calcium influx. Physiological reviews. 1997; 77(4):901-930.
41. Steinhardt RA and Alderton J. Intracellular free calcium rise triggers nuclear envelope breakdown in the sea urchin embryo. Nature. 1988; 332(6162):364-366.
42. Taylor JT, Zeng XB, Pottle JE, Lee K, Wang AR, Yi SG, Scruggs JA, Sikka SS and Li M. Calcium signaling and T-type calcium channels in cancer cell cycling. World journal of gastroenterology: WJG. 2008; 14(32):4984-4991.
43. Heise N, Palme D, Misovic M, Koka S, Rudner J, Lang F, Salih HR, Huber SM and Henke G. Non-selective cation channel-mediated Ca2+-entry and activation of Ca2+/calmodulin-dependent kinase II contribute to G2/M cell cycle arrest and survival of irradiated leukemia cells. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2010; 26(4-5):597-608.
44. Parkash J and Asotra K. Calcium wave signaling in cancer cells. Life sciences. 2010; 87(19-22):587-595.
45. Damm TB and Egli M. Calcium's role in mechanotransduction during muscle development. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2014; 33(2):249-272.
46. Fang KM, Chang WL, Wang SM, Su MJ and Wu ML. Arachidonic acid induces both Na+ and Ca2+ entry resulting in apoptosis. Journal of neurochemistry. 2008; 104(5):1177-1189.
47. Green DR and Reed JC. Mitochondria and apoptosis. Science. 1998; 281(5381):1309-1312.
48. Lang F and Hoffmann EK. Role of ion transport in control of apoptotic cell death. Comprehensive Physiology. 2012; 2(3):2037-2061.
49. Liu XH, Kirschenbaum A, Yu K, Yao S and Levine AC. Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line. The Journal of biological chemistry. 2005; 280(5):3817-3823.
50. Shaik N, Zbidah M and Lang F. Inhibition of Ca(2+) entry and suicidal erythrocyte death by naringin. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2012; 30(3):678-686.
51. Spassova MA, SoboloffJ, He LP, Hewavitharana T, Xu W, Venkatachalam K, van Rossum DB, Patterson RL and Gill DL. Calcium entry mediated by SOCs and TRP channels: variations and enigma. Biochimica et biophysica acta. 2004; 1742(1-3):9-20.
52. Svoboda N, Pruetting S, Grissmer S and Kerschbaum HH. cAMP-dependent chloride conductance evokes ammonia-induced blebbing in the microglial cell line, BV-2. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2009; 24(1-2):53-64.
53. Towhid ST, Schmidt EM, Tolios A, Munzer P, Schmid E, Borst O, Gawaz M, Stegmann E and Lang F. Stimulation of platelet death by vancomycin. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2013; 31(1):102-112.
54. Hers I, Vincent EE and Tavare JM. Akt signalling in health and disease. Cell Signal. 2011; 23(10):1515-1527.
55. Martelli AM, Evangelisti C, Chappell W, Abrams SL, Basecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo V, Ruvolo P, Kempf CR, Steelman LS and McCubrey JA. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia. 2011; 25(7):1064-1079.
56. Martelli AM, Tabellini G, Bortul R, Tazzari PL, Cappellini A, Billi AM and Cocco L. Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol Histopathol. 2005; 20(1):239-252.
57. Michl P and Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol. 2005; 43(10):1133-1139.
58. Osaki M, Oshimura M and Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004; 9(6):667-676.
59. Viglietto G, Amodio N, Malanga D, Scrima M and De Marco C. Contribution of PKB/AKT signaling to thyroid cancer. Front Biosci. 2011; 16:1461-1487.
60. Liu H, Huang Y, Zhang W, Sha Z, Li B, Yang Y, Liu W, Zhang C, Gao F and Cai J. Short-term hyperosmolality pretreatment on cells can reduce the radiosensitivity via RVI and Akt1 activation. Cell Physiol Biochem. 2013; 32(5):1487-1496.
61. Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A and Pili R. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget. 2013; 4(12):2225-2236.
62. Saturno G, Valenti M, De Haven Brandon A, Thomas GV, Eccles S, Clarke PA and Workman P. Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget. 2013; 4(8):1185-1198.
63. Peng H, Liu J, Sun Q, Chen R, Wang Y, Duan J, Li C, Li B, Jing Y, Chen X, Mao Q, Xu KF, Walker CL, Li J, Wang J and Zhang H. mTORC1 enhancement of STIM1-mediated store-operated Ca(2+) entry constrains tuberous sclerosis complex-related tumor development. Oncogene. 2012.
64. Amato R, Menniti M, Agosti V, Boito R, Costa N, Bond HM, Barbieri V, Tagliaferri P, Venuta S and Perrotti N. IL-2 signals through Sgk1 and inhibits proliferation and apoptosis in kidney cancer cells. J Mol Med (Berl). 2007; 85(7):707-721.
65. Lang F, Perrotti N and Stournaras C. Colorectal carcinoma cells-regulation of survival and growth by SGK1. Int J Biochem Cell Biol. 2010; 42(10):1571-1575.
66. Murakami Y, Hosoi F, Izumi H, Maruyama Y, Ureshino H, Watari K, Kohno K, Kuwano M and Ono M. Identification of sites subjected to serine/threonine phosphorylation by SGK1 affecting N-myc downstream-regulated gene 1 (NDRG1)/Cap43-dependent suppression of angiogenic CXC chemokine expression in human pancreatic cancer cells. Biochem Biophys Res Commun. 2010; 396(2):376-381.
67. Szmulewitz RZ, Chung E, Al Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, Stadler WM and Conzen SD. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012; 72(2):157-164.
68. Amato R, D'Antona L, Porciatti G, Agosti V, Menniti M, Rinaldo C, Costa N, Bellacchio E, Mattarocci S, Fuiano G, Soddu S, Paggi MG, Lang F and Perrotti N. Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. J Mol Med (Berl). 2009; 87(12):1221-1239.
69. Dehner M, Hadjihannas M, Weiske J, Huber O and Behrens J. Wnt signaling inhibits Forkhead box O3a-induced transcription and apoptosis through up-regulation of serum-and glucocorticoid-inducible kinase 1. J Biol Chem. 2008; 283(28):19201-19210.
70. Fagerli UM, Ullrich K, Stuhmer T, Holien T, Kochert K, Holt RU, Bruland O, Chatterjee M, Nogai H, Lenz G, Shaughnessy JD, Jr., Mathas S, Sundan A, Bargou RC, Dorken B, Borset M, et al. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells. Oncogene. 2011; 30(28):3198-3206.
71. Shanmugam I, Cheng G, Terranova PF, Thrasher JB, Thomas CP and Li B. Serum/glucocorticoid-induced protein kinase-1 facilitates androgen receptor-dependent cell survival. Cell Death Differ. 2007; 14(12):2085-2094.
72. Simon P, Schneck M, Hochstetter T, Koutsouki E, Mittelbronn M, Merseburger A, Weigert C, Niess A and Lang F. Differential regulation of serum-and glucocorticoid-inducible kinase 1 (SGK1) splice variants based on alternative initiation of transcription. Cell Physiol Biochem. 2007; 20(6):715-728.
73. Nasir O, Wang K, Foller M, Gu S, Bhandaru M, Ackermann TF, Boini KM, Mack A, Klingel K, Amato R, Perrotti N, Kuhl D, Behrens J, Stournaras C and Lang F. Relative resistance of SGK1 knockout mice against chemical carcinogenesis. IUBMB Life. 2009; 61(7):768-776.
74. Sherk AB, Frigo DE, Schnackenberg CG, Bray JD, Laping NJ, Trizna W, Hammond M, Patterson JR, Thompson SK, Kazmin D, Norris JD and McDonnell DP. Development of a small-molecule serum-and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res. 2008; 68(18):7475-7483.
75. Wang K, Gu S, Nasir O, Foller M, Ackermann TF, Klingel K, Kandolf R, Kuhl D, Stournaras C and Lang F. SGK1-dependent intestinal tumor growth in APC-deficient mice. Cell Physiol Biochem. 2010; 25(2-3):271-278.
76. Ackermann TF, Boini KM, Beier N, Scholz W, Fuchss T and Lang F. EMD638683, a novel SGK inhibitor with antihypertensive potency. Cell Physiol Biochem. 2011; 28(1):137-146.
77. Agarwal E, Brattain MG and Chowdhury S. Cell survival and metastasis regulation by Akt signaling in colorectal cancer. Cellular signalling. 2013; 25(8):1711-1719.
78. Gonzalez E and McGraw TE. The Akt kinases: isoform specificity in metabolism and cancer. Cell cycle. 2009; 8(16):2502-2508.
79. Yu Z, Xu Z, Disante G, Wright J, Wang M, Li Y, Zhao Q, Ren T, Ju X, Gutman E, Wang G, Addya S, Li T, Xiang Z, Wang C, Yang X, et al. miR-17/20 sensitization of breast cancer cells to chemotherapy-induced apoptosis requires Akt1. Oncotarget. 2014; 5(4):1083-1090.
80. Bruhn MA, Pearson RB, Hannan RD and Sheppard KE. Second AKT: the rise of SGK in cancer signalling. Growth factors. 2010; 28(6):394-408.
81. Faouzi M, Kischel P, Hague F, Ahidouch A, Benzerdjeb N, Sevestre H, Penner R and Ouadid-Ahidouch H. ORAI3 silencing alters cell proliferation and cell cycle progression via c-myc pathway in breast cancer cells. Biochimica et biophysica acta. 2013; 1833(3):752-760.
82. Hoth M and Niemeyer BA. The neglected CRAC proteins: Orai2, Orai3, and STIM2. Current topics in membranes. 2013; 71:237-271.
83. Motiani RK, Hyzinski-Garcia MC, Zhang X, Henkel MM, Abdullaev IF, Kuo YH, Matrougui K, Mongin AA and Trebak M. STIM1 and Orai1 mediate CRAC channel activity and are essential for human glioblastoma invasion. Pflugers Archiv: European journal of physiology. 2013; 465(9):1249-1260.
84. Chen J, Luan Y, Yu R, Zhang Z, Zhang J and Wang W. Transient receptor potential (TRP) channels, promising potential diagnostic and therapeutic tools for cancer. Bioscience trends. 2014; 8(1):1-10.
85. Kondratskyi A, Yassine M, Kondratska K, Skryma R, Slomianny C and Prevarskaya N. Calcium-permeable ion channels in control of autophagy and cancer. Frontiers in physiology. 2013; 4:272.
86. Lang F and Stournaras C. Ion channels in cancer: future perspectives and clinical potential. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2014; 369(1638):20130108.
87. Loughlin KR. Calcium channel blockers and prostate cancer. Urologic oncology. 2014.
88. Nielsen N, Lindemann O and Schwab A. TRP channels and STIM/ORAI proteins: Sensors and effectors of cancer and stroma cell migration. British journal of pharmacology. 2014.
89. Ohkubo T and Yamazaki J. T-type voltage-activated calcium channel Cav3.1, but not Cav3.2, is involved in the inhibition of proliferation and apoptosis in MCF-7 human breast cancer cells. International journal of oncology. 2012; 41(1):267-275.
90. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC and Ozols RF. Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer research. 1987; 47(2):414-418.
91. Louie KG, Behrens BC, Kinsella TJ, Hamilton TC, Grotzinger KR, McKoy WM, Winker MA and Ozols RF. Radiation survival parameters of antineoplastic drug-sensitive and-resistant human ovarian cancer cell lines and their modification by buthionine sulfoximine. Cancer research. 1985; 45(5):2110-2115.
92. Strese S, Fryknas M, Larsson R and Gullbo J. Effects of hypoxia on human cancer cell line chemosensitivity. BMC cancer. 2013; 13:331.
93. Borst O, Munzer P, Gatidis S, Schmidt EM, Schonberger T, Schmid E, Towhid ST, Stellos K, Seizer P, May AE, Lang F and Gawaz M. The inflammatory chemokine CXC motif ligand 16 triggers platelet activation and adhesion via CXC motif receptor 6-dependent phosphatidylinositide 3-kinase/Akt signaling. Circ Res. 2012; 111(10):1297-1307.
94. Feger M, Fajol A, Lebedeva A, Meissner A, Michael D, Voelkl J, Alesutan I, Schleicher E, Reichetzeder C, Hocher B, Qadri SM and Lang F. Effect of carbon monoxide donor CORM-2 on vitamin D3 metabolism. Kidney Blood Press Res. 2013; 37(4-5):496-505.
95. Borst O, Walker B, Munzer P, Russo A, Schmid E, Faggio C, Bigalke B, Laufer S, Gawaz M and Lang F. Skepinone-L, a novel potent and highly selective inhibitor of p38 MAP kinase, effectively impairs platelet activation and thrombus formation. Cell Physiol Biochem. 2013; 31(6):914-924.
96. Voelkl J, Mia S, Meissner A, Ahmed MS, Feger M, Elvira B, Walker B, Alessi DR, Alesutan I and Lang F. PKB/SGK-Resistant GSK-3 Signaling Following Unilateral Ureteral Obstruction. Kidney Blood Press Res. 2013; 38(1):156-164.
97. Bhavsar SK, Schmidt S, Bobbala D, Nurbaeva MK, Hosseinzadeh Z, Merches K, Fajol A, Wilmes J and Lang F. AMPKalpha1-Sensitivity of Orai1 and Ca Entry in T-Lymphocytes. Cell Physiol Biochem. 2013; 32(3):687-698.
98. Lichtenfels R, Rappl G, Hombach AA, Recktenwald CV, Dressler SP, Abken H and Seliger B. A proteomic view at T cell costimulation. PloS one. 2012; 7(4):e32994.
99. Bird GS, DeHaven WI, Smyth JT and Putney JW, Jr. Methods for studying store-operated calcium entry. Methods. 2008; 46(3):204-212.
100. Rotte A, Pasham V, Bhandaru M, Bobbala D, Zelenak C and Lang F. Rapamycin sensitive ROS formation and Na(+)/H(+) exchanger activity in dendritic cells. Cell Physiol Biochem. 2012; 29(3-4):543-550.